Abstract：
Lung transplant candidates who are highly sensitized against human leucocyte antigen present an ongoing challenge with regards to finding immunologically acceptable donors. Desensitization strategies aimed at reducing preformed donor-specific antibodies have a number of limitations. Imlifidase, an IgG-degrading enzyme derived from Streptococcus pyogenes, is a novel agent that has been used to convert positive crossmatches to negative in kidney transplant candidates, allowing transplantation to occur. We present the first case of imlifidase use for antibody depletion in a highly sensitized lung transplant candidate who went on to undergo a successful bilateral lung transplant.
摘要：
对人白细胞抗原高度致敏的肺移植候选者在寻找免疫学上可接受的供体方面提出了持续的挑战。旨在减少预先形成的供体特异性抗体的脱敏策略具有许多限制。imlifidase,一种来自化脓性链球菌的IgG降解酶，是一种新型药物，已用于将肾移植候选人的阳性交叉匹配转化为阴性，允许移植发生。我们介绍了在高度致敏的肺移植候选者中使用imlifidase进行抗体消耗的第一例，该候选者继续进行成功的双侧肺移植。
